In an elderly patient with dementia who is only on citalopram 10 mg daily, is very medication‑sensitive and small in size, what is the safest as‑needed (PRN) medication for anxiety or agitation that avoids strong benzodiazepines such as lorazepam?

Oral Quetiapine at Low Dose (12.5-25 mg PRN) is the Safest Option for This Patient

For your extremely medication-sensitive, small elderly patient with dementia experiencing terminal restlessness and mild agitation, oral quetiapine 12.5-25 mg PRN represents the safest pharmacological choice, with the most favorable safety profile compared to benzodiazepines or other antipsychotics. 1

Why Quetiapine is Preferred

The most recent 2025 geriatric emergency guidelines demonstrate that oral quetiapine has a favorable safety profile relative to alternative options for agitated elderly patients with dementia 1. This is particularly important given your patient's medication sensitivity and small size.

Key Safety Advantages:

• Lowest adverse event profile among antipsychotics studied in elderly dementia patients 1
• Oral formulation allows for lowest effective dosing and avoids the excessive risks of parenteral administration 1
• Dose-response relationship exists, meaning you can start extremely low (12.5 mg) and titrate cautiously 1

Why NOT Lorazepam (Despite Your Instinct)

You're right to be concerned about lorazepam. The evidence strongly supports avoiding it:

• Concerningly high frequencies of adverse events at higher doses and with parenteral administration 1
• Paradoxical worsening of agitation can occur in elderly patients given benzodiazepines 1
• FDA labeling warns that elderly/debilitated patients are more susceptible to sedative effects, with initial doses not exceeding 2 mg 2
• Increased fall risk and respiratory depression, especially problematic in small, frail patients 1
• The 2025 guidelines explicitly state that benzodiazepines pose significant risk to older adults with agitation 1

Practical Dosing Strategy

Start with quetiapine 12.5 mg PO PRN (can split a 25 mg tablet):

• Given his extreme medication sensitivity and small size, this ultra-low starting dose is appropriate
• Can increase to 25 mg if 12.5 mg proves insufficient and is well-tolerated
• The 2025 guidelines emphasize that starting with the lowest effective dose represents the safest strategy 1
• Monitor for sedation, orthostatic hypotension, and falls

Important Caveats

Before Using ANY Medication:

The APA guidelines mandate that antipsychotic medication should only be used when symptoms are severe, dangerous, and/or cause significant distress 3. For terminal restlessness with only "a little irritability," first ensure:

1. Non-pharmacological interventions have been exhausted: environmental modifications, reorientation, addressing pain/discomfort, caregiver engagement 1
2. Pain assessment is complete - unrecognized pain is a common contributor to agitation 3
3. Risk/benefit discussion with family/surrogate decision maker has occurred 3

Monitoring Requirements:

• Assess response with a quantitative measure (even simple documentation of frequency/severity) 3
• If no response after 4 weeks at adequate dose, taper and discontinue 3
• Watch for QT prolongation risk, especially since he's on citalopram (though at low dose) 4
• Monitor for extrapyramidal symptoms, though less common with quetiapine

Alternative if Quetiapine Unavailable

If quetiapine is not accessible, trazodone 25 mg PRN would be a reasonable second choice, though less evidence supports its use specifically for agitation in dementia. It has sedating properties without the benzodiazepine risks.

What About His Current Citalopram?

Interestingly, recent 2025 evidence shows citalopram does not significantly reduce agitation in Alzheimer's disease 5, 6, despite earlier studies suggesting benefit. His current 10 mg dose is unlikely contributing to agitation control, though it may be treating underlying depression or anxiety. The low dose (well below the 20 mg maximum for elderly) 4 minimizes QT risk when adding quetiapine.